InsiderTrades.com logo
This undiscovered CBD play is on the verge of disrupting the industry
From Emerging Markets Consulting   |   Ad
With recent health Canada approval they are poised to explode
Read more here

UTHR Insider Trading (United Therapeutics)

Insider Ownership Percentage: 10.90%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $30,328,981.60

United Therapeutics Insider Trading History Chart

United Therapeutics Share Price & Price History

$173.70
▲ +1.32 (0.77%)
As of 02/24/2021 01:00 AM ET
Days: 30 | 90 | 365
Are you looking for the next great pet stock play?
From Emerging Markets Consulting   |   Ad
Don't miss this opportunity as FRPT is already trading over 100 dollars per share!
Read more here about the next great pet stock!

United Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/8/2020Martine A RothblattCEOSell10,000$117.91$1,179,100.0010,140  
7/6/2020Martine A RothblattCEOSell10,000$119.60$1,196,000.0010,140  
7/2/2020Martine A RothblattCEOSell10,000$120.73$1,207,300.0010,140  
6/30/2020Martine A RothblattCEOSell10,000$120.36$1,203,600.0010,140  
6/29/2020Raymond DwekDirectorSell4,600$116.81$537,326.004,600  
6/26/2020Martine A RothblattCEOSell10,000$121.00$1,210,000.0010,140  
6/24/2020Martine A RothblattCEOSell30,000$119.54$3,586,200.0010,140  
6/22/2020Martine A RothblattCEOSell10,000$117.81$1,178,100.0010,140  
6/19/2020Martine A RothblattCEOSell20,000$116.35$2,327,000.0010,140  
6/17/2020Martine A RothblattCEOSell10,000$117.82$1,178,200.0010,140  
6/15/2020Martine A RothblattCEOSell10,000$113.87$1,138,700.0010,140  
6/12/2020Martine A RothblattCEOSell20,000$115.42$2,308,400.0010,140  
6/10/2020Martine A RothblattCEOSell30,000$122.86$3,685,800.0010,140  
6/8/2020Judy D OlianDirectorSell4,510$124.96$563,569.603,490  
6/5/2020Martine A RothblattCEOSell10,000$123.59$1,235,900.0010,140  
6/3/2020Martine A RothblattCEOSell10,000$124.52$1,245,200.0010,140  
6/1/2020Martine A RothblattCEOSell10,000$119.28$1,192,800.0010,140  
5/29/2020Martine A RothblattCEOSell10,000$115.91$1,159,100.0010,140  
5/27/2020Martine A RothblattCEOSell10,000$115.90$1,159,000.0010,140  
5/5/2020Tommy G ThompsonDirectorSell3,100$112.56$348,936.009,050  
4/20/2020Richard GiltnerDirectorSell5,000$107.00$535,000.008,750  
4/14/2020Richard GiltnerDirectorSell5,000$99.00$495,000.008,750  
3/26/2020Richard GiltnerDirectorSell5,000$91.75$458,750.008,750  
6/27/2019Raymond DwekDirectorSell3,750$76.11$285,412.503,750  
6/20/2019Richard GiltnerDirectorSell5,000$79.05$395,250.005,000  
3/7/2019Christopher PatuskyDirectorSell3,370$110.75$373,227.50  
2/5/2019Tommy G ThompsonDirectorSell400$117.00$46,800.002,970  
1/30/2019Martine A RothblattCEOSell14,108$115.77$1,633,283.167,194  
1/28/2019Martine A RothblattCEOSell14,108$115.37$1,627,639.967,194  
1/24/2019Martine A RothblattCEOSell7,054$113.95$803,803.307,194  
1/22/2019Martine A RothblattCEOSell7,054$113.35$799,570.907,194  
1/17/2019Martine A RothblattCEOSell14,108$113.70$1,604,079.607,194  
1/15/2019Martine A RothblattCEOSell14,108$114.85$1,620,303.807,194  
1/10/2019Martine A RothblattCEOSell14,108$113.51$1,601,399.087,194  
1/8/2019Martine A RothblattCEOSell7,054$113.16$798,230.647,195  
1/4/2019Martine A RothblattCEOSell7,055$111.51$786,703.051,540  
9/10/2018Christopher CauseyDirectorSell810$119.00$96,390.001,555  
9/6/2018Christopher CauseyDirectorSell810$118.00$95,580.003,925  
8/16/2018Richard GiltnerDirectorSell3,240$129.38$419,191.20  
8/3/2018Christopher CauseyDirectorSell580$127.48$73,938.401,605  
6/29/2018Raymond DwekDirectorSell3,240$113.07$366,346.80  
6/12/2018Judy D. OlianDirectorSell600$112.38$67,428.00  
4/9/2018Martine A RothblattCEOSell21,513$110.88$2,385,361.4421,653  
4/5/2018Martine A RothblattCEOSell21,512$114.30$2,458,821.6021,652  
4/3/2018Martine A RothblattCEOSell22,059$114.44$2,524,431.96687  
3/29/2018Martine A RothblattCEOSell43,024$111.14$4,781,687.3621,652  
3/22/2018Martine A RothblattCEOSell1,100$110.01$121,011.001,240  
3/20/2018Martine A RothblattCEOSell301$110.48$33,254.4821,652  
3/16/2018Martine A RothblattCEOSell43,025$111.11$4,780,507.7521,652  
3/14/2018Martine A RothblattCEOSell21,512$112.55$2,421,175.6021,652  
See Full Table

SEC Filings (Institutional Ownership Changes) for United Therapeutics (NASDAQ:UTHR)

90.09% of United Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

United Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in Company
2/24/2021Bank Julius Baer & Co. Ltd Zurich283$43K0.0%N/A0.001%
2/23/2021Principal Financial Group Inc.131,547$19.97M0.0%-0.4%0.296%
2/19/2021JPMorgan Chase & Co.130,418$19.80M0.0%-23.2%0.293%
2/18/2021Symmetry Partners LLC2,901$0.44M0.0%+13.9%0.007%
2/18/2021Truist Financial Corp6,569$1M0.0%N/A0.015%
2/17/2021SummerHaven Investment Management LLC3,527$0.54M0.4%N/A0.008%
2/17/2021Krensavage Asset Management LLC322,537$48.96M14.3%-24.3%0.726%
2/17/2021Advisor Partners LLC1,318$0.20M0.0%N/A0.003%
2/17/2021Kiwi Wealth Investments Limited Partnership1,942$0.30M0.0%-89.8%0.004%
2/16/2021SummerHaven Investment Management LLC535,363$0.54M0.4%N/A1.205%
2/16/2021Silverarc Capital Management LLC5,364$0.81M0.5%N/A0.012%
2/16/2021Squarepoint Ops LLC12,640$1.92M0.0%-29.6%0.028%
2/16/2021Morgan Stanley46,035$6.99M0.0%+88.2%0.104%
2/16/2021Nuveen Asset Management LLC497,558$75.52M0.0%-31.8%1.120%
2/16/2021Scopia Capital Management LP205,526$31.20M3.9%N/A0.462%
2/16/2021Captrust Financial Advisors2,209$0.34M0.0%+25.2%0.005%
2/16/2021Guggenheim Capital LLC38,315$5.82M0.0%-4.4%0.086%
2/16/2021Price T Rowe Associates Inc. MD243,501$36.96M0.0%+649.2%0.548%
2/16/2021Avoro Capital Advisors LLC2,850,000$432.60M7.5%N/A6.413%
2/16/2021Virginia Retirement Systems ET AL152,400$23.13M0.2%-1.8%0.343%
2/16/2021Schroder Investment Management Group111,348$16.90M0.0%-46.7%0.251%
2/16/2021Gyon Technologies Capital Management LP30,933$4.70M1.6%+310.5%0.070%
2/16/2021Janus Henderson Group PLC18,765$2.85M0.0%-30.6%0.042%
2/16/2021Prelude Capital Management LLC21,860$3.32M0.1%+2,436.0%0.049%
2/16/2021A.R.T. Advisors LLC2,257$0.34M1.6%-32.8%0.005%
2/16/2021ExodusPoint Capital Management LP37,188$5.65M0.1%+1,073.9%0.084%
2/16/2021Charles Schwab Investment Management Inc.350,600$53.22M0.0%+2.3%0.789%
2/13/2021Ontario Teachers Pension Plan Board7,096$1.08M0.0%N/A0.016%
2/13/2021American International Group Inc.80,177$12.17M0.0%-1.5%0.180%
2/12/2021Stifel Financial Corp6,222$0.95M0.0%+21.0%0.014%
2/12/2021Capital Impact Advisors LLC19,032$2.89M0.7%-13.7%0.043%
2/12/2021CWM Advisors LLC1,674$0.25M0.1%N/A0.004%
2/12/2021Federated Hermes Inc.19,602$2.98M0.0%+0.8%0.044%
2/12/2021LPL Financial LLC3,196$0.49M0.0%+32.9%0.007%
2/12/2021Public Employees Retirement System of Ohio26,030$3.95M0.0%+18.8%0.059%
2/12/2021The Manufacturers Life Insurance Company 53,351$8.10M0.0%-8.3%0.120%
2/12/2021Credit Suisse AG86,247$13.09M0.0%-2.8%0.194%
2/12/2021CSat Investment Advisory L.P.5,345$0.81M0.8%-26.3%0.012%
2/12/2021Virtus ETF Advisers LLC4,252$0.65M0.3%-16.0%0.010%
2/12/2021M&T Bank Corp1,394$0.21M0.0%N/A0.003%
2/12/2021Origin Asset Management LLP18,225$2.77M0.3%N/A0.041%
2/12/2021Mercer Global Advisors Inc. ADV5,084$0.77M0.0%+74.4%0.011%
2/12/2021Twin Tree Management LP29,375$4.46M0.0%+2,937,400.0%0.066%
2/11/2021Lazard Asset Management LLC245,791$37.31M0.0%+14.4%0.553%
2/11/2021Eqis Capital Management Inc.4,449$0.68M0.1%N/A0.010%
2/11/2021Globeflex Capital L P8,219$1.25M0.3%-1.0%0.018%
2/11/2021Fuller & Thaler Asset Management Inc.90,851$13.79M0.1%N/A0.204%
2/11/2021Brandes Investment Partners LP32,537$4.84M0.1%-45.6%0.073%
2/11/2021Northern Trust Corp350,392$53.19M0.0%-0.7%0.788%
2/11/2021Burney Co.11,596$1.76M0.1%-4.0%0.026%
2/11/2021Barclays PLC7,047$1.07M0.0%-28.1%0.016%
2/11/2021Handelsbanken Fonder AB8,300$1.26M0.0%+22.1%0.019%
2/11/2021Teacher Retirement System of Texas4,043$0.61M0.0%+60.1%0.009%
2/11/2021Skandinaviska Enskilda Banken AB publ 18,678$2.84M0.0%-17.3%0.042%
2/11/2021Veriti Management LLC887$0.14M0.0%N/A0.002%
2/11/2021Signaturefd LLC308$47K0.0%+54.0%0.001%
2/10/2021Rhumbline Advisers121,110$18.38M0.0%+5.3%0.273%
2/10/2021Renaissance Technologies LLC3,607,291$547.55M0.6%-2.7%8.117%
2/10/2021Mackenzie Financial Corp8,194$1.24M0.0%+4.4%0.018%
2/10/2021QS Investors LLC35,913$5.45M0.1%-0.2%0.081%
2/10/2021Assetmark Inc.187,178$28.41M0.2%+10.1%0.421%
2/10/2021Aviva PLC12,313$1.87M0.0%-44.8%0.028%
2/10/2021Panagora Asset Management Inc.202,414$30.72M0.2%+364.8%0.455%
2/10/2021KBC Group NV15,401$2.34M0.0%+180.4%0.035%
2/10/2021Tamarack Advisers LP183,000$28.11M5.9%+14.4%0.412%
2/9/2021Wells Fargo & Company MN304,726$46.25M0.0%-9.2%0.686%
2/9/2021Hancock Whitney Corp3,314$0.50M0.0%-2.7%0.007%
2/9/2021Duality Advisers LP6,591$1M0.1%-45.9%0.015%
2/9/2021Sawtooth Solutions LLC1,791$0.27M0.0%N/A0.004%
2/9/2021ClariVest Asset Management LLC4,663$0.71M0.0%+14,941.9%0.010%
2/9/2021Meeder Asset Management Inc.288$44K0.0%-96.1%0.001%
2/9/2021Donoghue Forlines LLC3,973$0.60M0.1%N/A0.009%
2/9/2021Bank of New York Mellon Corp502,520$76.28M0.0%+3.6%1.131%
2/9/2021Illinois Municipal Retirement Fund13,621$2.07M0.1%+88.3%0.031%
2/9/2021Nicollet Investment Management Inc.5,987$0.91M0.4%+3.6%0.013%
2/9/2021Oregon Public Employees Retirement Fund14,833$2.25M0.0%-1.5%0.033%
2/9/2021Chartwell Investment Partners LLC25,486$3.87M0.1%-14.2%0.057%
2/9/2021Campbell & CO Investment Adviser LLC1,710$0.26M0.2%-26.0%0.004%
2/9/2021ProShare Advisors LLC11,148$1.69M0.0%+2.0%0.025%
2/9/2021Profund Advisors LLC11,397$1.73M0.1%+15.5%0.026%
2/8/2021Royce & Associates LP143,200$21.74M0.2%+121.3%0.322%
2/8/2021Thompson Siegel & Walmsley LLC371,853$56.44M0.9%-13.4%0.837%
2/8/2021Alliancebernstein L.P.88,059$13.37M0.0%-0.4%0.198%
2/8/2021Principal Financial Group Inc.131,547$19.97M0.0%-0.4%0.296%
2/8/2021Seizert Capital Partners LLC77,201$11.72M0.7%-7.9%0.174%
2/8/2021State Board of Administration of Florida Retirement System63,430$9.63M0.0%-10.0%0.143%
2/8/2021New York State Common Retirement Fund59,898$9.09M0.0%-7.4%0.135%
2/8/2021Sei Investments Co.58,269$8.85M0.0%+99.7%0.131%
2/8/2021AGF Investments LLC5,662$0.86M0.1%-56.7%0.013%
2/8/2021AGF Investments Inc.1,384$0.21M0.0%-60.0%0.003%
2/8/2021Russell Investments Group Ltd.381,807$57.55M0.1%-13.8%0.859%
2/8/2021American Assets Investment Management LLC10,000$1.52M0.2%N/A0.023%
2/6/2021AJO LP21,793$3.31M0.3%-91.2%0.049%
2/6/2021Pzena Investment Management LLC4,289$0.65M0.0%-15.8%0.010%
2/5/2021BlackRock Inc.4,273,124$648.62M0.0%-0.8%9.615%
2/5/2021Aperio Group LLC47,075$7.15M0.0%+12.7%0.106%
2/5/2021Swiss National Bank100,400$15.24M0.0%+0.6%0.226%
2/5/2021Sumitomo Mitsui Trust Holdings Inc.4,200$0.64M0.0%-68.9%0.009%
2/5/2021SG Americas Securities LLC7,914$1.20M0.0%-62.6%0.018%
2/5/2021US Bancorp DE2,420$0.37M0.0%-53.5%0.005%
Data available starting January 2016

See Full Table
United Therapeutics logo
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and internationally. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma. It also engages in developing OreniPro, RemoPro, Treprostinil Technosphere, Trevyent, Ralinepag, and Aurora-GT to treat PAH; LNG01 to treat IPF; Unexisome to treat BPD; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, biomechanical lungs, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. The company has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder, and Dreamboat and Cricket devices; Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH; and Samumed LLC to develop LNG01. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
Read More

Today's Range

Now: $173.70
$169.08
$181.14

50 Day Range

MA: $168.36
$155.79
$174.85

52 Week Range

Now: $173.70
$75.58
$181.14

Volume

462,332 shs

Average Volume

324,816 shs

Market Capitalization

$7.72 billion

P/E Ratio

16.43

Dividend Yield

N/A

Beta

0.52

Who are the company insiders with the largest holdings of United Therapeutics?

United Therapeutics' top insider shareholders include:
  1. Martine A Rothblatt (CEO)
  2. Tommy G Thompson (Director)
  3. Richard Giltner (Director)
  4. Raymond Dwek (Director)
  5. Judy D Olian (Director)
  6. Christopher Patusky (Director)

Who are the major institutional investors of United Therapeutics?

United Therapeutics' top institutional investors include:
  1. BlackRock Inc. — 9.62%
  2. Renaissance Technologies LLC — 8.12%
  3. Avoro Capital Advisors LLC — 6.41%
  4. First Trust Advisors LP — 1.91%
  5. SummerHaven Investment Management LLC — 1.20%
  6. Bank of New York Mellon Corp — 1.13%

Which major investors are selling United Therapeutics stock?

In the last quarter, UTHR stock was sold by these institutional investors:
  1. Nuveen Asset Management LLC
  2. AJO LP
  3. State of Michigan Retirement System
  4. Krensavage Asset Management LLC
  5. Renaissance Technologies LLC
  6. Schroder Investment Management Group
  7. Russell Investments Group Ltd.
  8. Thompson Siegel & Walmsley LLC
In the last year, company insiders that have sold United Therapeutics company stock include:
  1. Martine A Rothblatt (CEO)
  2. Tommy G Thompson (Director)
  3. Richard Giltner (Director)
  4. Raymond Dwek (Director)
  5. Judy D Olian (Director)

Which major investors are buying United Therapeutics stock?

Within the last quarter, UTHR stock was purchased by institutional investors including:
  1. Avoro Capital Advisors LLC
  2. SummerHaven Investment Management LLC
  3. Price T Rowe Associates Inc. MD
  4. Scopia Capital Management LP
  5. Panagora Asset Management Inc.
  6. Fuller & Thaler Asset Management Inc.
  7. Royce & Associates LP
  8. ExodusPoint Capital Management LP
This undiscovered CBD play is on the verge of disrupting the industry
From Emerging Markets Consulting   |   Ad
With recent health Canada approval they are poised to explode
Read more here